Acadia Pharmaceuticals (ACAD) Short-term Investments (2016 - 2025)
Historic Short-term Investments for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to $589.0 million.
- Acadia Pharmaceuticals' Short-term Investments rose 4360.08% to $589.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $589.0 million, marking a year-over-year increase of 4360.08%. This contributed to the annual value of $436.4 million for FY2024, which is 7441.65% up from last year.
- Per Acadia Pharmaceuticals' latest filing, its Short-term Investments stood at $589.0 million for Q3 2025, which was up 4360.08% from $508.4 million recorded in Q2 2025.
- Over the past 5 years, Acadia Pharmaceuticals' Short-term Investments peaked at $589.0 million during Q3 2025, and registered a low of $112.0 million during Q1 2023.
- Moreover, its 5-year median value for Short-term Investments was $296.5 million (2022), whereas its average is $335.7 million.
- Per our database at Business Quant, Acadia Pharmaceuticals' Short-term Investments crashed by 5354.71% in 2023 and then soared by 13734.57% in 2024.
- Quarter analysis of 5 years shows Acadia Pharmaceuticals' Short-term Investments stood at $373.3 million in 2021, then dropped by 19.1% to $302.0 million in 2022, then dropped by 17.14% to $250.2 million in 2023, then skyrocketed by 74.42% to $436.4 million in 2024, then soared by 34.97% to $589.0 million in 2025.
- Its Short-term Investments was $589.0 million in Q3 2025, compared to $508.4 million in Q2 2025 and $463.9 million in Q1 2025.